Literature DB >> 12592316

25. Immunotherapy of allergic disease.

Anthony J Frew1.   

Abstract

Specific immunotherapy involves the administration of allergen extracts to achieve clinical tolerance of the allergens which cause symptoms in patients with allergic conditions. Immunotherapy has been shown to be effective in patients with mild forms of allergic disease, and also in those who do not respond well to standard drug therapy. Recent studies suggest that specific immunotherapy may also modify the course of allergic disease, by reducing the risk of developing new allergic sensitizations, and also inhibiting the development of clinical asthma in children treated for allergic rhinitis. Specific immunotherapy remains the treatment of choice for patients with systemic allergic reactions to wasp and bee stings. The precise mechanisms responsible for the beneficial effects of SIT remain a matter of research and debate. An effect on regulatory T cells seems most probable, associated with switching of allergen-specific B cells towards IgG4 production. Few direct comparisons of specific immunotherapy and drug therapy have been made. Existing data suggest that the effects of specific immunotherapy take longer to come on, but once established, specific immunotherapy will give long-lasting relief of allergic symptoms, whereas the benefits of drugs only last as long as they are continued.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12592316     DOI: 10.1067/mai.2003.84

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

Review 1.  Pollen immunotherapy: selection,prevention, and future directions.

Authors:  Steven J McEldowney; Robert K Bush
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

2.  Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice.

Authors:  K Kitagaki; T R Businga; J N Kline
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses.

Authors:  Hidenori Takagi; Takachika Hiroi; Lijun Yang; Yoshifumi Tada; Yoshikazu Yuki; Kaoru Takamura; Ryotaro Ishimitsu; Hideyuki Kawauchi; Hiroshi Kiyono; Fumio Takaiwa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-08       Impact factor: 11.205

4.  Construction of a Der p2-transgenic plant for the alleviation of airway inflammation.

Authors:  C C Lee; H Ho; K T Lee; S T Jeng; B L Chiang
Journal:  Cell Mol Immunol       Date:  2011-05-23       Impact factor: 11.530

5.  Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI).

Authors:  Eric Leith; Tom Bowen; Joe Butchey; David Fischer; Harold Kim; Bill Moote; Peter Small; Don Stark; Susan Waserman
Journal:  Allergy Asthma Clin Immunol       Date:  2006-06-15       Impact factor: 3.406

Review 6.  [Specific immunotherapy. Hyposensitization with allergens].

Authors:  B Wedi; A Kapp
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

Review 7.  Mimotope vaccination--from allergy to cancer.

Authors:  Regina Knittelfelder; Angelika B Riemer; Erika Jensen-Jarolim
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

8.  Expression of hypoallergenic Der f 2 derivatives with altered intramolecular disulphide bonds induces the formation of novel ER-derived protein bodies in transgenic rice seeds.

Authors:  Lijun Yang; Sakiko Hirose; Kazuya Suzuki; Takachika Hiroi; Fumio Takaiwa
Journal:  J Exp Bot       Date:  2012-02-29       Impact factor: 6.992

9.  Actual therapeutic management of allergic and hyperreactive nasal disorders.

Authors:  Claudia Rudack
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28

10.  Patient's compliance with allergen immunotherapy.

Authors:  Cristoforo Incorvaia; Marina Mauro; Erminia Ridolo; Paola Puccinelli; Massimiliano Liuzzo; Silvia Scurati; Franco Frati
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.